Cargando…
Impact of KRAS Mutations on Management of Colorectal Carcinoma
The epidermal growth factor receptor (EGFR) pathway is a therapeutic target in the management of colorectal cancer (CRC). EGFR antagonists are active in this disease; however, only a subset of patients respond to such therapy. A Kirsten ras sarcoma viral oncogene (KRAS) wild-type (WT) status of the...
Autores principales: | Sullivan, Kevin M., Kozuch, Peter S. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
SAGE-Hindawi Access to Research
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062096/ https://www.ncbi.nlm.nih.gov/pubmed/21437184 http://dx.doi.org/10.4061/2011/219309 |
Ejemplares similares
-
KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009) -
The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
por: Tria, Simon Manuel, et al.
Publicado: (2023) -
IMPACT OF KRAS MUTATIONS IN CLINICAL FEATURES IN COLORECTAL
CANCER
por: ZANATTO, Renato Morato, et al.
Publicado: (2020) -
Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma
por: Palomba, Grazia, et al.
Publicado: (2016) -
Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
por: Arrington, Amanda K., et al.
Publicado: (2012)